Skip to main content
SpringerLink
Log in

Semaglutide and risk of suicidal ideations

  • Research Briefing
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Semaglutide, also known as Ozempic for treating type 2 diabetes and as Wegovy for treating obesity, compared with other weight management or diabetic medications, is not associated with higher risk of suicidal ideations in patients with obesity (or who are overweight) or patients with type 2 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Associations of semaglutide with incident suicidal ideations.

References

  1. Ilic, M. & Ilic, I. Worldwide suicide mortality trends (2000-2019): A joinpoint regression analysis. World J. Psychiatry 12, 1044–1060 (2022). This paper reports worldwide suicide outcomes.

    Article  PubMed  PubMed Central  Google Scholar 

  2. World Health Organization. Suicide; https://www.who.int/news-room/fact-sheets/detail/suicide (2023). This report presents global statistics of suicide.

  3. European Medicines Agency. EMA statement on ongoing review of GLP-1 receptor agonists. EMA; https://www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists (2023). This statement presents the EMA warning of risk for suicidal ideations with semaglutide.

  4. Wang, L. et al. Association of COVID-19 with new-onset Alzheimer’s Disease. J. Alzheimer’s Dis. 89, 411–414 (2022). This article presents our previous retrospective cohort study using similar patient EHR analysis.

    Article  CAS  Google Scholar 

  5. Wang, L. et al. Incidence rates and clinical outcomes of SARS-CoV-2 infection with the Omicron and Delta variants in children younger than 5 years in the US. JAMA Pediatr. 176, 811–813 (2022). This article presents our previous retrospective cohort study analyzing patient EHRs to gather robust real-time and real-world data to help inform health policy and patient decision making during the COVID-19 pandemic.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Wang, W. et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat. Med. https://doi.org/10.1038/s41591-023-02672-2 (2024).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Semaglutide and risk of suicidal ideations. Nat Med 30, 45–46 (2024). https://doi.org/10.1038/s41591-023-02691-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-023-02691-z

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation